Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum.

Francisca Sivera,Victoria Núñez-Monje,Cristina Campos-Fernández,Isabel Balaguer-Trull,Montserrat Robustillo-Villarino,Marta Aguilar-Zamora,Marta Garijo-Bufort, Juan Miguel López-Gómez,Carolina Peña-González,Isabel de la Morena,Diego Bedoya-Sanchís,Liliya Yankova-Komsalova,Arantxa Conesa-Mateos,Anna Martínez-Cristóbal, Francisco Javier Navarro-Blasco,José Miguel Senabre-Gallego,Juan José Alegre-Sancho

Frontiers in medicine（2023）

引用 0|浏览11

暂无评分

摘要

Secukinumab improved disease activity in axSpA patients, especially in naive, and second-line patients, which was accompanied by high persistence rates up to 24 months.

查看译文

关键词

secukinumab, effectiveness, axial spondyloarthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, real-world evidence

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要